Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis Lovenox patents

Executive Summary

Aventis will not file patent infringement lawsuit against Amphastar to enforce Lovenox patent No. 4,692,435, set to expire in December 2004. Aventis' defense against enoxaparin generics is focused on the re-issuance of another patent (No. 5,389,618) that will expire in February 2012. The company received a 30-month stay of approval based on a suit against Amphastar and Teva on the original '618 patent (1"The Pink Sheet" Aug. 18, 2003, p. 16)...

You may also be interested in...

Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay

Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition

Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits

California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts